Market Overview

I think you’ll love what you hear, what you’ll see and the opportunities that will be set before you.
- Jon Najarian
GET TICKETS

Melinta Therapeutics Shares Up 200% After FDA Accepts sNDA For Bacterial Pneumonia Drug

Share:
Melinta Therapeutics Shares Up 200% After FDA Accepts sNDA For Bacterial Pneumonia Drug

Melinta Therapeutics (NASDAQ: MLNT) shares are trading higher after the company said the FDA accepted a supplemental New Drug Application (sNDA) for priority review of its BAXDELA sNDA for the treatment of community acquired bacterial pneumonia.

"Due to the rise of antibiotic resistance and an aging population, community-acquired bacterial pneumonia, or CABP, remains a challenge for healthcare professionals and has led to a need for new treatment options," said Sue Cammarata, chief medical officer of Melinta.

"BAXDELA's potency and activity against the most common bacterial pathogens seen in CABP indicate it could play a significant role in the treatment of this life-threatening illness, if approved. We look forward to working with the FDA to help evaluate bringing this potential option to people with CABP as soon as possible."

Melinta Therapeutics shares were trading up 201% at $5.96 at time of publication.

Related Links:

Sorrento Therapeutics Could IPO Its Scilex Unit

ThermoGenesis Cord Blood Processing System Wins Health Canada Approval

Posted-In: BAXDELANews FDA Movers Trading Ideas Best of Benzinga

 

Related Articles (MLNT)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Apple Analyst: Shift Away From Chinese Production Would Be 'Gargantuan Endeavor'

Federal Measures To Protect Cannabis Users In Legal States Head To House Floor